Orthocell Ltd has released a press release.
Remplir gains momentum in nerve-sparing prostate surgery
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Orthocell
- 2nd Distributor in Canada, Entire $75m Market Now Covered
- Remplir Launches in Hong Kong with First Surgical Case
- HK Distributor Signed as Remplir Expands in the Asian Market
- OCC Secures Rights to High-Value Bone Regeneration Tech
- $30m Placement Sees Orthocell Positioned for Rapid Growth
Later from Orthocell
- Remplir™ Nerve Sparing Prostate Cancer Surgery Commercial Opportunity Gathers Momentum with ~100 Surgeries Now Performed with Multiple Surgeons Nationwide
- First Commercial Sales of Remplir Achieved in Hong Kong
- Remplir Regulatory Application for US$750m EU-UK Market
- Orthocell Hits US Milestone - 100 Remplir Units Sold.
- Orthocell Posts Seventh Straight Record Revenue Quarter
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell